A newly released Pessary Market analysis report by Future Market Insights shows that global sales of the Pessary Market in 2021 were held at US$ 289.8 Million. With a CAGR of 10.2%, the market is projected to reach a valuation of US$ 831.3 Million by 2032. Ring Pessary is expected to be the highest revenue-generating category, projected to register a CAGR of 11.2% from 2022 to 2032.
| Attributes | Details |
|---|---|
| Global Pessary Market Size (2022) | US$ 316 Million |
| Global Pessary Market Size (2032) | US$ 831.3 Million |
| Global Pessary Market CAGR (2022 to 2032) | 10.2% |
| USA Pessary Market CAGR (2022 to 2032) | 11.1% |
| Key Companies Covered |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Pessary Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Pessary Market increased at around 8.5% CAGR.
The aging population, together with pessaries' high success rate, has been driving the growth of the pessary market. Furthermore, lifestyle-related diseases are becoming more prevalent. The growing prevalence of diseases like pelvic organ prolapse and urinary incontinence will drive the pessary market. Furthermore, growing global awareness of the importance of pessaries during pelvic organ prolapse complications will serve as a growth driver.
For women with POP who want nonsurgical management, a future pregnancy, early-stage prolapse, or are too frail for surgery, pessaries are typically recommended as a first-line treatment option. Patients whose stress incontinence is aggravated by strenuous physical activity may benefit from pessaries. Pessaries provide an opportunity to simulate postsurgical conditions and help patients' expectations regarding symptom reduction in women who present with pelvic pain, back pain, and pressure thought to be caused by POP operations.
Several studies on the success rate of pessary fitting have been conducted, with results ranging from 41% to 74%. Success rates as high as 62 percent have been observed in patients with stage III and IV prolapse, suggesting that pessaries are an excellent option for all populations with severe POP. In the United States, approximately 200,000 POP operations are performed each year. Although not life-threatening, POP could have a major impact on women's standard of living.
The Fourth International Consultation on Incontinence recommends pessaries, pelvic floor muscle training, and lifestyle counseling as conservative management options for women with Pelvic Organ Prolapse. Vaginal vault prolapse, or some other type of pelvic organ prolapse, affects approximately half of the women aged 50 to 80 years. Childbirth, age, fatness, gastrointestinal issues, or a hysterectomy can all cause uterine prolapse and increase the demand for pessaries.
Because they provide simple, affordable, and safe solutions, vaginal pessaries are a popular treatment option for organ prolapse and incontinence. These factors contribute to the higher patient satisfaction rate in comparison to an alternate solution. As a result, pessaries are now preferred as first-line treatment for POP or stress urinary incontinence.
Among the key factors expected to drive the market during the forecast period are frequent product introductions, a strong emphasis on Research and Development by market players and universities, geographical expansion by key players, and a number of government initiatives. The United Kingdom Clinical Guideline for Proper Procedure in the Use of Vaginal Pessaries for POP is a document prepared by medical professionals and supporters of prolapse pessaries. The goal of the Guideline is to provide multidisciplinary healthcare professionals with guidance and information on best practices in pessary use for prolapse.
Principal Consultant
Pessaries are now made of non-reactive silicone and come in a variety of designs and sizes to accommodate everyone. Silicon has low surface tension and remarkable chemical stability, allowing for biocompatibility and bio-durability in many long-term implant applications, making it suitable for medical applications.
Pessaries can be used as a stopgap measure for women who want to stop having children or are waiting for surgery. It can also be used as a long-term solution for women who do not qualify for surgery.
In June 2021, using artificial intelligence-driven machine learning and 3D design, Femtherapeutics Inc. developed a device to relieve urinary incontinence and discomfort in women suffering from pelvic organ prolapse. Unlike traditional pessaries, which can cause irritation and penetrate soft tissues, resulting in bleeding, the custom-made pessary is intended to support displaced vaginal tissues caused by the condition.
Asia Pacific is the most lucrative region with double-digit projected growth. The fastest rate of expansion in the regional finance industry is predicted to result from younger, expanding populations and a growing focus on wellness.
As the elderly are more prone to incontinence and prolapsed organ disorders (POP), there is a sizable market in this region, with Japan, China, and India being the primary suppliers. Medical tourism is also a key driver behind the market's growth here.
In developing countries, the extent and effects of morbidity associated with pelvic organ prolapse are rarely acknowledged due to patient embarrassment. However, research funded by the United Nations Population Fund (UNFPA) in Nepal has begun to identify the suffering of women from this disorder. UNFPA is assisting in the identification of women with pelvic organ prolapse through reproductive health camps and the hiring of gynecologists to treat these women at district hospitals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The USA is expected to have the largest market of US$ 323.2 Million by the end of 2032 with North America being the dominant player and accounting for over 35% of total sales. With the elderly population in the United States increasing, there is renewed interest in pessaries as a less invasive alternative to surgical repair for pelvic organ prolapse (POP).
They are an excellent choice for women who have not finished having children, do not want surgery, or are ineligible for surgery. Patients suffering from POP and stress urinary incontinence may benefit from long-term pessary use. Although serious side effects are uncommon, many patients find it difficult to insert and remove most pessary types. The design of pessaries should continue to improve, making their use more appealing.
Women in the USA have an 11% lifetime risk of having prolapse or incontinence surgery by the age of 80, with a 30% chance of reoperation after four years. The number of women over the age of 65 in the USA is expected to more than double to reach more than 40 million by 2030, according to the USA Census Bureau.
As the United States population ages, there is renewed interest in the use of pessaries. According to a survey conducted by the American Urogynaecology Society, 77% of those polled used pessaries as their first-line POP therapy. The pessary is still a viable treatment option for prolapse and incontinence.
The market in the United Kingdom is expected to gross US$ 42 Million by 2032. The market in the country is expected to witness a CAGR of 12.1% during the forecast period, registering an absolute dollar opportunity of US$ 28.2 Million.
In Japan, the market is expected to reach a valuation of US$ 30 Million by 2032. With an absolute dollar opportunity of US$ 20.7 Million during the forecast period, the market is expected to register a CAGR of 12.7%.
The market in South Korea is expected to gross an absolute dollar opportunity of US$ 9.9 Million by 2032. Growing at a CAGR of 10.8% from 2022 to 2032, the market is likely to reach a valuation of US$ 15.5 Million.
The Ring Pessary segment is forecasted to grow at the highest CAGR of over 11% from 2022 to 2032. Because of their ease of insertion and removal, ring pessaries are typically the first-line pessary for clinicians. They can be used at any stage of POP, but the first and second stages are the most common. The catheter is unfolded once above the pubic symphysis after being inserted into the vagina. The pessary is gently pulled and folded in half to be removed. To help with insertion and removal, a string can be attached to the ring. Patients can easily learn how to do this on their own.
A new disposable, non-invasive vaginal ring pessary is used at home to treat a variety of pelvic floor disorders. The ConTIPI Medical ProVate, for example, is made of a flexible skeleton covered by a soft elastomer and is designed to expand in the vagina, separating the lateral vaginal walls and mechanically preventing cervical and vault descent as well as blocking further descent of the anterior and posterior walls within the rings hollow.
The Hospitals segment is forecasted to grow at the highest CAGR of over 11.4% from 2022 to 2032. With 45% of the total revenue, the hospital segment dominated the vaginal pessary market. This could be attributed to the rising market demand for pessaries among post-operative and hospitalized indwellings. Among factors contributing to the segment's growth is the heightened interest in the notion of organ prolapse, urinary incontinence, and the inclusion of pessaries in private insurance policies. Surgeons are increasingly favoring minimally invasive procedures that will limit post-operation complications and increase recovery times.
Among the leading players in the global Pessary market are Integra Lifesciences, Panpac Medical Corporation, Personal Medical Corporation, Dr. Arabin GmbH & Co., and Wallach Surgical Devices. To gain a competitive advantage in the industry, these market players are investing in product launches, partnerships, mergers and acquisitions, and expansions.
Some of the recent developments in the pessary market are mentioned below:
The Liv Labs pessary is soft, smooth, and squishy, making insertion and removal easier. It is made of medical-grade silicone. Women can use it whenever they want, whether it is all day or just for a quick trip to the gym.
Similarly, the team at Future Market Insights, which is available in the full report, has tracked recent developments related to companies in the Pessary market
The global market is worth more than US$ 289.8 Million at present.
The value of the Pessary Market is projected to increase at a CAGR of around 10.2% from 2022 to 2032.
The value of the Pessary Market increased at a CAGR of around 8.5% from 2017 to 2021.
The increasing incidence of pelvic organ prolapse (POP), and urinary incontinence amongst the majority of women, stand as the key trend in the Pessary market.
The pessary Market in the USA is projected to expand at a CAGR of around 11.1% from 2022 to 2032.
1. Executive Summary | Pessary Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Investment Feasibility Matrix
3.4. PESTLE and Porter’s Analysis
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2022 to 2032
5.3.1. Gellhorn
5.3.2. Ring
5.3.3. Donut
5.3.4. Other Types
5.4. Y-o-Y Growth Trend Analysis By Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Type, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centres
6.3.3. Clinics
6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. Middle East and Africa(MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Rest of Latin America
9.2.2. By Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. United Kingdom
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By End User
10.4. Key Takeaways
11. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By End User
11.4. Key Takeaways
12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By End User
12.4. Key Takeaways
13. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Type
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Rest of Middle East and Africa(MEA)
14.2.2. By Type
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Type
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Type
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Type
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Type
15.4.2.2. By End User
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Type
15.5.2.2. By End User
15.6. Germany
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Type
15.6.2.2. By End User
15.7. Italy
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Type
15.7.2.2. By End User
15.8. France
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Type
15.8.2.2. By End User
15.9. United Kingdom
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Type
15.9.2.2. By End User
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Type
15.10.2.2. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Type
15.11.2.2. By End User
15.12. BENELUX
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Type
15.12.2.2. By End User
15.13. China
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Type
15.13.2.2. By End User
15.14. Japan
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Type
15.14.2.2. By End User
15.15. South Korea
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Type
15.15.2.2. By End User
15.16. India
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Type
15.16.2.2. By End User
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Type
15.17.2.2. By End User
15.18. Malaysia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Type
15.18.2.2. By End User
15.19. Indonesia
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Type
15.19.2.2. By End User
15.20. Australia
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Type
15.20.2.2. By End User
15.21. New Zealand
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2021
15.21.2.1. By Type
15.21.2.2. By End User
15.22. GCC Countries
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2021
15.22.2.1. By Type
15.22.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. MedGyn Products, Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Cooper Surgical Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Personal Medical Corp.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Panpac Medical Corp
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Smiths Medical
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Thomas Medical
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Artisan Medical
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Bioteque America, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Integra LifeSciences Corporation
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Dr. Arabin GmbH & Co.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Medgyn Products, Inc.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. Wallach Surgical Devices
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Pessary Market
